Nrf2 (nuclear factor erythroid-derived 2-like 2) had aroused interest as a therapeutic target in the treatment of metabolic diseases because of its ability to regulate about 250 genes involved in the adaptive response to antioxidants and xenobiotics, under physiological and pathological conditions [9,10]. The gene discussed is NFE2L2; the disease is Other metabolic disease.